公开(公告)号：US20240360156A1

公开(公告)日：2024-10-31

申请号：US18592897

申请日：2024-03-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I):




wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20190263832A1

公开(公告)日：2019-08-29

申请号：US16256773

申请日：2019-01-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20200317692A1

公开(公告)日：2020-10-08

申请号：US16827316

申请日：2020-03-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20180162875A1

公开(公告)日：2018-06-14

申请号：US15845621

申请日：2017-12-18

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20170022222A1

公开(公告)日：2017-01-26

申请号：US15289650

申请日：2016-10-10

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Abstract translation: 其中每个符号如说明书中所定义，或其盐，其具有AMPA（α-氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体增强作用。 本发明的化合物可用作抑郁症，精神分裂症，阿尔茨海默病或注意缺陷多动障碍（ADHD）等的预防或治疗药物。

公开(公告)号：US20150073137A1

公开(公告)日：2015-03-12

申请号：US14540699

申请日：2014-11-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20140228320A1

公开(公告)日：2014-08-14

申请号：US14253139

申请日：2014-04-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiko TANIGUCHI ,  Masato YOSHIKAWA ,  Kasei MIURA ,  Tomoaki HASUI ,  Eiji HONDA ,  Keisuke IMAMURA ,  Makoto KAMATA ,  Haruhi KAMISAKI ,  John F. QUINN ,  Joseph RAKER ,  Fatoumata CAMARA ,  Yi WANG

IPC: C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D498/04 ,  C07F7/10

CPC classification number: A61K31/4353 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/551 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07D471/14 ,  C07D473/00 ,  C07D473/28 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D498/08 ,  C07D519/00 ,  C07F7/10

Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia or so on represented by the formula (I):

Abstract translation: 本发明提供具有PDE抑制作用的化合物，其可用作预防或治疗由式（I）表示的精神分裂症等的药剂：

公开(公告)号：US20150353578A1

公开(公告)日：2015-12-10

申请号：US14804935

申请日：2015-07-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Abstract translation: 提供由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐，其具有AMPA（α-氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体 增效作用 本发明的化合物可用作抑郁症，精神分裂症，阿尔茨海默病或注意缺陷多动障碍（ADHD）等的预防或治疗药物。

公开(公告)号：US20140080817A1

公开(公告)日：2014-03-20

申请号：US13774707

申请日：2013-02-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Abstract translation: 提供由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐，其具有AMPA（α-氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体 增效作用 本发明的化合物可用作抑郁症，精神分裂症，阿尔茨海默病或注意缺陷多动障碍（ADHD）等的预防或治疗药物。

公开(公告)号：US20130303553A1

公开(公告)日：2013-11-14

申请号：US13944370

申请日：2013-07-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiko TANIGUCHI ,  Masato YOSHIKAWA ,  Kasei MIURA ,  Tomoaki HASUI ,  Eiji HONDA ,  Keisuke IMAMURA ,  Makoto KAMATA ,  Haruhi KAMISAKI

IPC: C07D471/04 ,  C07D473/00 ,  C07D498/04

CPC classification number: A61K31/4353 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/551 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07D471/14 ,  C07D473/00 ,  C07D473/28 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D498/08 ,  C07D519/00 ,  C07F7/10

Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.

Abstract translation: 本发明提供具有PDE抑制作用的化合物，其可用作预防或治疗精神分裂症的药剂。 化合物由式（I）表示：其中符号在说明书中定义。